IL-17A in COVID-19 Cases: A meta-analysis
| dc.contributor.author | Fadlallah, Sukayna M. | |
| dc.contributor.author | Sham Eddin, Marcel S. | |
| dc.contributor.author | Rahal, Elias A. | |
| dc.contributor.department | Experimental Pathology, Microbiology, and Immunology | |
| dc.contributor.department | Specialized Clinical Programs and Services | |
| dc.contributor.department | Center for Infectious Diseases Research | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:39:07Z | |
| dc.date.available | 2025-01-24T11:39:07Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Introduction: Numerous reviews, commentaries and opinion pieces have suggested targeting IL-17A as part of managing Coronavirus disease 2019 (COVID-19), the notorious pandemic caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). IL-17A is a proinflammatory cytokine attributed with homeostatic roles but that is also involved in autoimmune disease pathogenesis. While some studies have reported an increase in IL-17A in COVID-19 cases, no significant associations were found by others. Hence, we undertook this meta-analysis to study serum IL-17A levels in COVID-19 patients in relation to disease severity. Methodology: Multiple databases were systematically reviewed for literature published on the topic from January 1, 2019 to April 30, 2021. A random effects model was used to calculate weighted mean differences (WMDs) and 95% confidence interval (CIs) as well as the τ2 and I2 statistics for heterogeneity analysis. Results: We report that IL-17A increases in COVID-19 subjects irrespective of disease severity compared to controls [WMD = 2.51 pg/ml (95% CI 1.73-3.28), p < 0.00001]. It is also higher in patients with moderate disease compared to controls [WMD = 2.41 pg/ml (95% CI:1.40-3.43), p < 0.00001] as well as higher in patients with severe COVID-19 [WMD = 4.13 pg/ml (95% CI:1.65-6.60), p = 0.001]. While the increase in serum levels in subjects with severe disease over those with moderate disease was statistically significant, the association was not as robust as the other comparisons [WMD = 2.07 pg/ml (95% CI:0.20-3.95), p = 0.03]. Variable heterogeneity was observed in the various analyses with no significant publication bias detected. Conclusions: Hence, IL-17A may be of relevance when considering management approaches to COVID-19. Copyright © 2021 Fadlallah et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
| dc.identifier.doi | https://doi.org/10.3855/JIDC.15285 | |
| dc.identifier.eid | 2-s2.0-85122132876 | |
| dc.identifier.pmid | 34898490 | |
| dc.identifier.uri | http://hdl.handle.net/10938/29181 | |
| dc.language.iso | en | |
| dc.publisher | Journal of Infection in Developing Countries | |
| dc.relation.ispartof | Journal of Infection in Developing Countries | |
| dc.source | Scopus | |
| dc.subject | Covid-19 | |
| dc.subject | Il-17a | |
| dc.subject | Sars-cov-2 | |
| dc.subject | Global health | |
| dc.subject | Humans | |
| dc.subject | Interleukin-17 | |
| dc.subject | Pandemics | |
| dc.subject | Interleukin 17 | |
| dc.subject | Il17a protein, human | |
| dc.subject | Article | |
| dc.subject | Blood sampling | |
| dc.subject | Clinical outcome | |
| dc.subject | Coronavirus disease 2019 | |
| dc.subject | Disease severity | |
| dc.subject | Hospital admission | |
| dc.subject | Human | |
| dc.subject | Immune response | |
| dc.subject | Meta analysis | |
| dc.subject | Severe acute respiratory syndrome coronavirus 2 | |
| dc.subject | Systematic review | |
| dc.subject | Th17 cell | |
| dc.subject | Blood | |
| dc.subject | Pandemic | |
| dc.title | IL-17A in COVID-19 Cases: A meta-analysis | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1